Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase II for Secondary CNS Lymphoma. According to GlobalData, Phase II drugs for Secondary CNS Lymphoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Iopofosine i-131 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iopofosine i-131 overview
Iopofosine I-131 (CLR-131) is under development for the treatment of waldenstrom macroglobulinemia, refractory and relapsed multiple myeloma, chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), primary and secondary central nervous system lymphoma, marginal zone lymphoma (MZL), ependymoma, mantle cell lymphoma (MCL), solid tumors, neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), mycosis fungoides, head and neck cancer squamous cell carcinoma. The drug candidate is administered through intravenous route in the form of solution. It comprises of PLE, 18-(p-[I-131] iodophenyl) octadecyl phosphocholine, covalently labelled with iodine-131. It is being developed based on Phospholipid Drug Conjugate (PDC) delivery platform.
The drug candidate was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.
Cellectar Biosciences overview
Cellectar Biosciences (Cellectar) is a biopharmaceutical company. It focuses on developing innovative cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform, which targets specific tumor cell changes for effective, selective therapy. The company’s lead product candidate, iopofosine I 131, delivers iodine-131 directly to cancer cells, minimizing healthy tissue exposure. Iopofosine is being evaluated for several indications, including lymphoplasmacytic lymphoma (LPL), Waldenstrom’s macroglobulinemia (WM), relapsed/refractory multiple myeloma (r/r MM), and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It is also being studied for neuroblastoma, soft tissue sarcomas, and other pediatric cancers. Cellectar is headquartered in Florham Park, New Jersey, the US.
For a complete picture of Iopofosine i-131’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
